poisar

Stocks · News reference

ADARx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates

Fiscal.ai

ADARx Pharmaceuticals reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline and recent financing activities.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — ADARx Pharmaceuticals, Inc. (ADRX)

    Filed: 2026-09-28 AccNo: 0001193125-26-405297 Size: 193 KB Item 3.02: Unregistered Sales of Equity Securities Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits